INTRODUCTION
Chronic liver disease with cirrhosis is the 12th leading cause of death in the United States, with 31 903 cirrhosis-related deaths per 100 000 population reported in 2010. 1 Hepatic encephalopathy (HE) is a complication of cirrhosis associated with various degrees of neuropsychiatric impairment and neuromuscular dysfunction. 2 In patients with cirrhosis, HE may be classified within the spectrum of neurocognitive impairment as minimal (covert) HE, with subtle alterations in cognitive function, assessed by neuropsychometric testing, or overt HE, of varying severity, characterised clinically by alterations in consciousness, disorientation and generalised motor dysfunction (e.g. asterixis). [2] [3] [4] [5] [6] [7] [8] [9] Minimal HE may affect between approximately 30% and 70% of patients with cirrhosis. 10, 11 Although patients with minimal HE appear clinically to be asymptomatic, the condition still has a significant negative impact on patients' quality of life and daily functioning, including an increased risk of falls, poor driving performance, progression to overt HE, hospitalisations and death. 3, 6, 7, 12 Within their lifetime, overt HE is observed in 30-45% of patients with cirrhosis 5, 12 and represents a significant cause of hospitalisations, with an annual nationwide inpatient incidence of about 100 000 (0.33% of total hospitalisations). 13 The prognosis for patients who develop overt HE is poor; a population-based cohort study reported a 1-year survival rate of 36%.
14 Although the pathophysiology of HE has not been fully elucidated, researchers hypothesise that the accumulation of gut-derived toxins (especially ammonia), from bacteria, inflammation and oxidative stress, causes cerebral oedema, which underlies the symptoms of HE. [15] [16] [17] This accumulation of toxins is related to decreased liver function and the development of portosystemic shunts, thereby limiting the ability of the liver to effectively remove toxins from the bloodstream. 18 Enteric bacterial translocation is also an issue in patients with cirrhosis, and its pathogenesis is thought to be influenced by increased intestinal permeability, immunological impairment and the presence of small intestinal bacterial overgrowth. 19 Bacterial translocation in the presence of portosystemic shunting can increase the levels of systemic gut-derived toxins [e.g. lipopolysaccharides (LPS)], playing a role in the development of HE, 18, 20 but bacterial translocation also predisposes patients to infection [e.g. spontaneous bacterial peritonitis (SBP), septicaemia]. [18] [19] [20] In a pooled analysis, 11 987
patients with cirrhosis and any bacterial infection had a mortality rate of 43.5%, compared with a mortality rate of 13.6% for 2317 patients without a reported infection. 21 Overall, bacterial infection increased the risk of mortality by 3.8-fold in patients with cirrhosis, and therefore bacterial infection should be considered an important prognostic factor in patients with cirrhosis. As a consequence of the known pathophysiology of HE, treatment of HE episodes (e.g. with lactulose or nonsystemic antibiotics) is aimed at controlling potential precipitating factors of HE [e.g. infections, gastrointestinal (GI) bleeding] and reducing the production and circulating levels of gut-derived toxins (e.g. ammonia). 2 In addition, prophylactic therapy is recommended in patients who have had a previous episode of HE to prevent HE recurrence. 2 Rifaximin is a nonsystemic antibiotic that is available in 41 countries worldwide and was approved in the United States in 2010 to reduce the risk of overt HE recurrence in adults. Data have shown the efficacy and safety of daily rifaximin maintenance therapy for the prevention of HE recurrence. [22] [23] [24] [25] Among the various properties that make rifaximin a recommended treatment for this indication, the agent has antibiotic effects on a variety of GI aerobic and anaerobic bacteria. 26, 27 Although randomised comparative trials have not been conducted, rifaximin has a favourable safety profile for long-term administration relative to that reported for oral systemic antibiotics, [22] [23] [24] [25] which are associated with rare, serious events of nephrotoxicity, ototoxicity and peripheral neuropathy when administered long term. 2, 23 This narrative review briefly highlights the role of rifaximin in the management of HE and other complications of cirrhosis, with a focus on potential mechanisms of action and the need for future studies. A search of PubMed was conducted using the keywords 'rifaximin' AND ('hepatic encephalopathy' OR 'ascites' OR 'variceal bleeding' OR 'peritonitis' OR 'portal hypertension' OR 'portopulmonary hypertension' OR 'hepatorenal syndrome') to identify articles in English. Recent HE review articles, original research studies, and data sets presented at specialty conferences were considered for general information on cirrhosis of the liver and its complications. Bibliographies from included articles were manually reviewed for additional relevant studies.
CLINICAL PROFILE OF RIFAXIMIN
Hepatic encephalopathy Globally, rifaximin has been investigated or used in the treatment of HE for ≥30 years. In an early study of 32 patients with cirrhosis, elevated blood ammonia levels and symptoms of HE, rifaximin reduced serum ammonia 
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• Post hoc, 'crossover' analysis • Analysis of patient population (n = 82) treated for 6 months with placebo followed by 6 months of rifaximin 550 mg b.d.
• • Comparable improvements in signs and symptoms of HE were observed between rifaximin and nonabsorbable disaccharides • There was less abdominal pain in patients treated with rifaximin (P = 0.04) and a similar effect between groups for diarrhoea (P = 0.90) and significantly improved neurological signs and symptoms of overt HE. 28 Rifaximin has subsequently been evaluated in numerous studies for the treatment of acute episodes of HE and for the prevention of HE recurrence, including several randomised or open-label long-term studies (Table 1) . A relatively large body of evidence has established the beneficial effects of rifaximin on cirrhosis-related neuropsychiatric and neuromotor abnormalities of varying severity and duration. Most studies of rifaximin evaluated a 200-mg dose formulation, with a total daily dose of 1200 mg (400 mg t.d.s.). 30, 32-34, 37, 39-42, 45 However, with the development of a 550-mg dose formulation, more recent studies have evaluated 1100 mg/day (550 mg b.d.), [22] [23] [24] [25] and the latter dose represents the US recommended dose for maintenance of HE remission. 47 The largest randomised controlled trial (RCT) to date of rifaximin in the management of HE was a doubleblind, placebo-controlled phase 3 trial conducted in patients with cirrhosis in remission, but with a history of ≥2 overt HE episodes during the previous 6 months. 23 Patients were randomly assigned to 6 months of treatment with rifaximin 550 mg b.d. vs. placebo for maintenance of overt HE remission. In addition,~91% of patients in each group received concomitant lactulose. Rifaximin was associated with a 58% reduction in the relative risk (RR) of experiencing overt HE recurrence [hazard ratio (HR), 0.42; 95% confidence interval (CI), 0.28-0.64; P < 0.001]. The number needed to treat (NNT) to prevent one overt HE episode during the 6-month period was four patients. Rifaximin also decreased the risk of an HE-related hospitalisation compared with placebo, showing a 50% risk reduction (HR, 0.50; 95% CI, 0.29-0.87; P = 0.01) and NNT of 9 to prevent one HE-related hospitalisation during 6 months of treatment. 23 An open-label study of long-term (≥24 months) maintenance therapy with rifaximin 550 mg b.d. noted benefits on rates of HE-related hospitalisation [0.21 events per person-year of exposure (PYE)] that were similar to the results observed in the 'historic' rifaximin group from the RCT cited above 23 (0.30 events per PYE) and lower than results observed with the historic placebo group during the RCT 23 (0.72 events per PYE). 22 The maintenance study also indicated no increase in the rate of infections, and that antibiotic use generally did not increase with long-term rifaximin exposure. 22 In a separate post hoc analysis, 25 patients who crossed over to
rifaximin in the open-label study from placebo in the RCT 23 achieved a 79% reduction in the risk of experiencing an overt HE episode compared with their prior placebo experience in the RCT (HR, 0.21; 95% CI, 0.10-0.44; P < 0.0001), and a trend towards a reduction in HE-related hospitalisations was observed during the first 6 months of rifaximin treatment during the open-label phase relative to placebo treatment. 25 The rates and profile of adverse events during treatment with rifaximin in the open-label study were similar to those observed for the same patients during placebo treatment in the RCT.
In a study by Sharma et al., 44 patients with overt HE and a model for end-stage liver disease (MELD) score of 25 were randomly assigned to rifaximin plus lactulose or lactulose monotherapy. Approximately three quarters of patients (76%) in the rifaximin plus lactulose group compared with less than half of patients (44%) treated with lactulose monotherapy had complete resolution of HE (P = 0.004). Rifaximin plus lactulose also reduced mortality after treatment compared with lactulose monotherapy (23.8% vs. 49.1%; P < 0.05). Furthermore, more deaths were attributed to sepsis in the lactulose monotherapy group (P = 0.01). In addition, rifaximin plus lactulose was associated with a shorter hospital stay than lactulose monotherapy (5.8 vs. 8.2 days; P = 0.001).
44 • Rifaximin increased mean arterial pressure (P = 0.05), consistent with increase in systemic vascular resistance (P = 0.01) and decrease in cardiac output (P = 0.02) • Rifaximin improved renal function, assessed as increase in GFR (P = 0.006) and urinary sodium excretion (P = 0.03) • Rifaximin decreased plasma renin activity (P = 0.02) and plasma endotoxin (P = 0.005), IL-6 (P = 0.01), and TNF-a (P = 0.02) levels A 2014 meta-analysis of 19 RCTs including 1370 patients with minimal or overt HE supported the finding that rifaximin has a beneficial effect on prevention of HE recurrence. 46 Rifaximin treatment was more likely to fully resolve an HE episode compared with a control group (RR, 1.34; 95% CI, 1.11-1.62), and rifaximin reduced the risk of mortality (RR, 0.64; 95% CI, 0.43-0.94). 46 The impact on mortality, however, was only based on a few studies that actually analysed this endpoint; therefore, further studies are needed to evaluate the impact of rifaximin on this important outcome.
Other complications of cirrhosis
Although most studies of rifaximin in patients with cirrhosis have focused on HE, several studies have evaluated the impact of rifaximin in preventing other complications of cirrhosis ( 22, 24 A relatively small increase in the incidence of C. difficile infection was also observed with rifaximin in the pivotal, randomised, double-blind, placebo-controlled study, although mitigating circumstances were noted and patients recovered with treatment. 23 As with any antibacterial agent, the Warnings and Precautions section of the rifaximin prescribing information makes note of the risk of C. difficile infection. The effect of rifaximin on overall patient survival initially reported by Sharma et al. 44 and Vlachogiannakos et al. 49 has been supported by a meta-analysis of rifaximin treatment for HE. 46 In an interesting study by Kalambokis et al., 50 the effect of rifaximin on renal function and hemodynamics was assessed in patients with alcohol-related cirrhosis and ascites. Rifaximin improved both systemic hemodynamic function (increased mean arterial pressure and systemic vascular resistance; decreased cardiac output) and renal function (increased glomerular filtration rate and urinary sodium excretion). Rifaximin also reduced serum levels of endotoxin and proinflammatory mediators, including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a). 50 These data suggest that the efficacy of rifaximin may not be limited to its direct antibiotic actions. Thus, the mechanisms of action that underlie the clinical efficacy of rifaximin have been the subject of ongoing investigation.
POTENTIAL MECHANISMS OF ACTION OF RIFAXIMIN
A number of mechanisms of action have been proposed to account for the clinical efficacy of rifaximin in HE and its potential benefits for other complications of cirrhosis. The varied activities of rifaximin may include altering gut microbiota composition, modulating gut microbiota function, and influencing bile acid, inflammatory mediator and neurotoxin levels involved in mediating the complications of cirrhosis.
Impact of rifaximin on gut microbiota composition
The gut microbiota is altered in patients with cirrhosis, and investigators are only now beginning to characterise these differences, along with potential changes that may be associated with disease progression. 51 The ratio of beneficial to potentially harmful bacterial taxa, or the cirrhosis dysbiosis ratio (CDR), has been proposed as a measure of changes in the gut microbiota. Examples of benign and autochthonous gut taxa include Lachnospiraceae, Ruminococcaceae and Clostridiales XIV, whereas Enterobacteriaceae and Bacteroidaceae are considered pathogenic. A low CDR may indicate a deficit in beneficial bacteria, an overabundance of harmful taxa, or a combination of both. Altered functionality of bacteria has also been shown in patients with cirrhosis. 52 Progressive changes in the gut microbiota were observed in patients with worsening cirrhosis, such that the CDR was significantly reduced in patients with progressive liver disease. 51 The lowest CDRs were measured in patients with cirrhosis who developed HE or infections; these patients were correspondingly at highest risk of mortality. Progressive increases in cirrhosis disease severity (i.e. decreasing CDR) were associated with increases in pathogenic taxa, such as Enterococcaceae, Staphylococcaceae and Enterobacteriaceae, and reductions in autochthonous taxa. 51 For example, in patients who developed HE, low CDR was driven primarily by an increase in Enterobacteriaceae and to a lesser extent by Bacteroidaceae, with no change in the abundance of beneficial taxa. In contrast, the gut microbiota and CDR were unchanged over time in patients with stable liver disease, a finding that suggests the CDR may be a useful tool for assessing prognosis and response to treatment. 51 Although the cause of dysbiosis in cirrhosis is not well established, one hypothesis suggests that changes in bile acid levels and composition affect the gut microbiota in a manner that favours the overgrowth of pathogenic and proinflammatory bacterial species. 53 A group of highly conserved commensal or autochthonous bacteria derive energy from the conversion of primary bile acids to secondary bile acids. 54 Secondary bile acids [e.g. deoxycholic acid (DCA)] can be associated with membrane destabilisation and increased intestinal permeability, and can also impact gut microbiota composition. [55] [56] [57] A change in the ratio of secondary to primary bile acids may favour pathogenic taxa. Indeed, in the presence of lower numbers of 7a-dehydroxylating bacteria secondary to reductions in primary bile acids, the ratio of secondary to primary bile acids decreases. 53 Data suggest that patients with cirrhosis secrete a lower concentration of bile acids into the small intestine, thereby promoting gut microbiota dysbiosis (Figure 1 ). 53 In turn, mucosal and systemic inflammation associated with dysbiosis may be attributed to the increase in the number of organisms that produce potent LPS (e.g. Enterobacteriaceae).
Inflammation associated with cirrhosis leads to further reductions in bile acid synthesis, enabling further bacte- , normal levels of bile salts are metabolised from cholesterol in the neutral bile acid biosynthetic pathway. 7a-dehydroxylating bacteria thrive from energy derived from normal levels of primary bile acids, and the ratio of secondary to primary bile acids is normal. In contrast, in the liver of patients with cirrhosis (right), inflammation shifts cholesterol metabolism to the acidic pathway, and more of the secondary bile acid deoxycholic acid is produced. The ratio of secondary to primary bile acids is reduced due to lower bile acid synthesis. (see also accompanying text). 7a-DeOH, 7a-dehydroxylating; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; EHC, enterohepatic circulation; LCA, lithocholic acid; LPS, lipopolysaccharide. Reprinted with permission from Ridlon et al.
53
rial growth and LPS production in a positive feedback loop. Of note, rifaximin appears to suppress faecal DCA levels and alter the secondary/primary bile acid ratio in patients with compensated cirrhosis. 58 This could be associated with reduced endotoxemia and harmful metabolite levels. These effects are observed without meaningful changes in the overall gut microbiota structure (i.e. composition). 53 The effects of rifaximin on the secondary/primary bile acid ratio probably do not translate into alterations in gut dysbiosis beyond that associated with liver disease severity. In a study of the effects of rifaximin on the mucosal gut microbiota, concomitant rifaximin and lactulose significantly affected the mucosal microbiota composition compared with lactulose alone (Table 3) . 59 Specifically, there was a significant decrease in the abundance of Roseburia, Blautia and Veillonellaceae and a concomitant increase in the abundance of Propionibacterium in the rifaximin plus lactulose group vs. lactulose alone. However, this difference in the mucosal microbiota might reflect the more severe form of liver disease of patients receiving rifaximin plus lactulose vs. lactulose alone, and not the direct result of the presence of rifaximin. 59 As such, no substantial difference in the faecal microbiota composition was observed between patients with HE or without HE, including those on rifaximin therapy. 59 In another study of patients with compensated cirrhosis and minimal HE treated for 8 weeks with rifaximin 550 mg b.d., there was a significant reduction in Veillonellaceae and an increase in Eubacteriaceae bacterial taxa in faecal samples. 60 Elevated Veillonellaceae in the stool or colonic mucosa of patients with cirrhosis may signify HE or minimal HE. Despite alterations in certain taxa, there were no broad compositional changes in faecal microbiota in patients with minimal HE treated with rifaximin. 60 Evidence is emerging that rifaximin may select for changes in gut microbiota that favour beneficial species, without significant changes in the overall relative abundance of bacteria. These modulatory activities on gut microbiota bacterial composition may, in part, underlie the clinical efficacy of rifaximin in reducing gut-derived toxins and markers of inflammation that contribute to the development of HE and other complications of cirrhosis. 
Effects of rifaximin on gut microbiota function
Rifaximin may improve cognitive function by modulating gut microbiota and their associated end-products. 60 In a study of 20 patients with minimal HE treated with rifaximin 550 mg b.d. for 8 weeks, rifaximin improved cognition in six of seven tests performed, favourably changed test performance of patients undergoing functional magnetic resonance imaging, and improved white matter integrity (P < 0.01). 60, 61 Although the study was not designed to assess specific actions of rifaximin on cognitive function, results of a serum metabolomics analysis suggested that rifaximin altered bacterial end-products ( Figure 2 ). 60 Rifaximin was associated with increases in saturated fatty acids (caprylic, myristic and palmitic acid) and unsaturated fatty acids (linolenic, gamma-linolenic, linoleic and arachidonic acid), along with increases in intermediates of carbohydrate metabolism (fructose, succinic acid and citramalic acid). 60 Increased serum levels of fatty acid intermediaries may alter brain function (cognition). 62 Correlation networks showed that the relationship between the metabolome and microbiota was altered by rifaximin for bacterial families associated with cirrhosis, HE and cognitive dysfunction, including Porphyromonadaceae, Bacteroidaceae and Enterobacteriaceae. 60 In contrast, changes in faecal microbiota composition were modest in the context of changes observed in bacterial function. These results support a hypothesis that a primary action of rifaximin involves modulation of bacterial metabolic function rather than reduction in overall bacterial abundance. 60 Additionally, correlation networks suggested that rifaximin selected for beneficial bacterial species; that is, the drug selected for species linked with less oxidative stress and aromatic amino acid and nitrogen production. 60 In summary, the data suggest that rifaximin-mediated changes in microbiota-associated metabolic function may translate into a beneficial impact on cognition in patients with HE. 60 The precise mechanism(s) of rifaximin-mediated improvement in cognitive function requires further investigation.
Anti-inflammatory effects of rifaximin
Cirrhosis is associated with an intestinal, hepatic and systemic proinflammatory state. 50 Cirrhosis-related bacterial overgrowth and translocation increase endotoxin levels and circulating levels of proinflammatory cytokines, including TNF-a and IL-6, which may contribute to the pathogenesis of complications of cirrhosis. 63 Patients with HE show elevations in circulating levels of several markers of inflammation, including IL-10, IL-6, IL-2, IL-13 and TNF-a. Increased levels of proinflammatory serum cytokines IL-2, IL-13 and IL-23 have been associated with bacterial species Enterobacteriaceae, Veillonellaceae and Fusobacteriaceae. It is noteworthy that rifaximin reduced levels of members of the Veillonellaceae family, which have been implicated in the pathogenesis of cirrhosis-associated inflammation. 60 Data have shown that rifaximin reduces endotoxin (e.g. LPS) levels, an action that may improve the host inflammatory milieu. 50 Rifaximin 1200 mg/day for 4 weeks has been shown to reduce serum endotoxin levels and proinflammatory mediators (e.g. IL-6, TNF-a) in patients with cirrhosis. 50 The investigators attributed the clinical benefits of rifaximin treatment to a reduction in intestinal bacterial products.
FUTURE DIRECTIONS
Because changes in the GI microenvironment may cause HE and other complications of cirrhosis, agents that modulate this environment may be well suited for the management of these conditions. Several studies of rifaximin in the management of cirrhosis-related complications are planned or currently ongoing (Table 4) . [64] [65] [66] [67] [68] [69] A phase 2, dose-ranging study is underway to assess a new formulation of rifaximin (soluble solid dispersion) for the prevention of complications of liver cirrhosis, 66 including efficacy in reducing the rates of hospitalisation attributed to complications of liver disease, all-cause mortality rates and incidences of overt HE, SBP, variceal bleeding and hepatorenal syndrome. Studies are also assessing the contributions of bacterial overgrowth and intestinal transit time to the development of HE, and determining the mechanisms by which rifaximin changes the GI microenvironment and clinical outcomes. 64, 65 Separately and in aggregate, the outcomes of these studies should help further elucidate the potential role and mechanisms of action of rifaximin in the management of cirrhosis-related complications.
CONCLUSIONS
The GI microenvironment and associated gut microbiota play an important role in the pathogenesis of HE and other complications of cirrhosis (Figure 3) . Modulation of this microenvironment appears to have a beneficial impact on the gut-liver-brain axis and, consequently, on patient outcomes. The nonsystemic agent rifaximin has been shown to be efficacious for treatment of overt HE episodes, with improvement in neuromotor function and cognition, and for long-term (≥24 months) prevention of HE recurrence. Evidence is emerging that rifaximin exerts its beneficial effects through a number of potential mechanisms of action ( Figure 4) . Although rifaximin appears to have limited effects on modulating the overall structure of gut microbiota, it may alter the ratio of beneficial to harmful taxa, the latter of which are strongly correlated with cognitive impairment. Additionally, although rifaximin does not appear to cause global changes in bacterial composition of the gut microbiota, it appears to modulate the function of the gut microbiota. Rifaximin reduces the load of gut-derived toxins by decreasing production and circulating levels, in addition to reducing proinflammatory cytokine levels. Although preliminary, these data on the function of the gut microbiota and other modulatory activities support the use of rifaximin for the management of HE and other complications of cirrhosis. However, future studies are needed to further characterise the activities of rifaximin in the setting of cirrhosis.
